文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

新生儿临床试验中的安全性报告:对实现最佳且全球适用方法的思考

Safety reporting in neonatal clinical trials: reflections towards optimal, globally relevant approaches.
PubMed 文献 · Trials · 2025-02-09

本文为评论文章,讨论新生儿临床试验中不良事件收集与安全性报告面临的挑战,指出新生儿人群异质性高、合并症多,安全性评估与记录尤为困难;新生儿药物研发与剂量优化正受到监管机构关注,但仍需改进不良事件收集方法,使其与试验结局匹配并减轻试验站点负担,在资源有限地区更需务实的安全性报告策略。

要点

  • 新生儿人群异质性高、合并症多,不良事件评估与记录尤为困难。
  • 新生儿药物研发与剂量优化正受到监管机构关注,但不良事件收集仍需改进。
  • 安全性报告方法应与试验结局匹配以减轻试验站点负担,资源有限地区尤需务实策略。

核心结论

  • 新生儿临床试验中不良事件收集是证据生成的关键部分,但需进一步努力确保不良事件得到充分收集以生成必需的安全性数据。
  • 安全性报告方法应与预期试验结局相匹配,以尽量减少对试验站点的负担。
  • 在资源有限、药物警戒实施尤为困难的地区,鉴于对有效药物的重大公共卫生需求,务实的安全性报告方法更为重要。

研究设计与样本

  • 本文为评论文章,反思新生儿临床试验安全性报告中的挑战与未来可改进的潜在领域。

主要发现

  • 新生儿是异质性人群且合并症发生率高,使不良事件评估与记录尤为困难。
  • 新生儿研究在药物开发及针对该人群的最佳剂量需求方面正受到监管机构关注。
  • 在资源有限地区,药物警戒的实施可能尤为困难。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adverse event (AE) collection is a key part of evidence generation in clinical trials and an integral element of safety reporting. AE assessment and documentation is particularly challenging in neonates who are a heterogeneous population with high rates of co-morbidities. Neonatal research is finally gaining the attention of regulators regarding drug development and the need for optimal dosing specific to this population. However, further efforts are necessary to ensure that adverse events (AEs) are adequately collected, allowing for the generation of essential safety data. It is also crucial that the methodology used aligns with the intended trial outcomes to minimise the burden on trial sites. In resource-constrained settings, where pharmacovigilance implementation can be particularly challenging, a pragmatic approach to safety reporting is even more important given the significant public health need for effective drugs. This commentary reflects on some of the challenges and potential areas of improvement in safety reporting that could be addressed in future neonatal-focused trials.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Hill LF, Obiero CW, Bekker A, et al. Safety reporting in neonatal clinical trials: reflections towards optimal, globally relevant approaches. Trials. 2025. PMID: 39924475. doi:10.1186/s13063-025-08723-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。